Thyroid Hormone and Neuronal Protection

甲状腺激素和神经元保护

基本信息

项目摘要

Thyroid hormone (TH) is essential for normal brain development and may also promote recovery and neuronal regeneration after brain injury. TH acts predominantly through the nuclear receptors, TH receptor alpha (THRA) and beta (THRB). Additional factors that impact TH action in the brain include metabolism, activation of thyroxine (T4) to triiodothyronine (T3) by the enzyme 5′-deiodinase Type 2 (Dio2), inactivation by the enzyme 5-deiodinase Type 3 (Dio3) to reverse T3 (rT3), which occurs in glial cells, and uptake by the Mct8 transporter in neurons. Traumatic brain injury (TBI) is associated with inflammation, metabolic alterations and neuronal death. In clinical studies, serum levels of T4 and T3, as well as TH levels in the brain, are reduced. We have utilized rodent models of TBI to demonstrate that treatment with T4, 1 hour after injury, is protective, reduces edema, and promotes neuronal recovery. We have identified similar protective effects of TH in an in vitro model of neuronal injury from hypoxia. We will study both the mechanism of TH protection from neuronal injury as well as optimize protective treatment strategies with TH, utilizing in vivo rodent models of TBI. We have preliminary data identifying genes whose expression is impacted by hypoxic neuronal injury and those that are normalized by TH treatment. We will characterize these genes to identify specific pathways influenced by TH treatment. Hypoxic injury increases histone methylation in neurons and this is reduced by T3 treatment. We believe that this is an important mechanism for T3 protection after injury. We will also identify T3-stimulated pathways that activate neural regeneration and anti-apoptosis in neurons after hypoxic injury. We will utilize in vivo rodent models of TBI to identify the actions of TH in protection and promotion of recovery after brain injury and determine the optimal thyroid hormone treatment after TBI. We will use a mouse with global expression of a T3-reporter to determine specific brain regions with reduced T3 action after injury, as well as assess the response to systemic TH treatment after injury. We will also investigate the mechanism of TH treatment reduction in brain edema by studying the regulation of water transport. We will determine the optimal thyroid hormone preparation, dose and treatment schedule to promote brain recovery and neural regeneration in rodent models of TBI. The response to TH therapy will include assessment of the brain lesion by imaging, brain region-specific patterns of gene expression and behavioral studies. TH reduction in brain edema and cell death, and promotion of neuronal regeneration, should provide a beneficial effect after brain injury. These studies should provide guidance for clinical strategies to use TH to reduce the impact of brain injury and promote recovery. !
甲状腺骑马(Th)对于正常的大脑发育至关重要,也可能促进康复和 脑损伤后神经元再生。这主要通过核接收器起作用 受体α(THRA)和β(THRB)。影响大脑行动的其他因素包括 代谢,甲状腺素(T4)通过酶5'-二碘酶2型的三碘甲醇(T3)的激活(T3) (dio2),酶5-二二二氨二酶3(dio3)灭活至反向T3(RT3),该酶发生在胶质中 细胞,以及MCT8转运蛋白在神经元中的摄取。创伤性脑损伤(TBI)与 在临床研究中,血清T4和T3水平, 以及大脑中的TH水平降低。我们已经利用TBI的啮齿动物模型来证明 受伤后1小时的T4治疗受到保护,减少水肿并促进神经元 恢复。我们已经确定了TH在从 缺氧。我们将研究保护免受神经元损伤的保护机制,并优化 使用TBI的体内啮齿动物模型,使用TH的保护性处理策略。我们有初步数据 识别其表达受到低氧神经损伤影响的基因 通过TH治疗归一化。我们将表征这些基因以识别受影响的特定途径 通过治疗。低氧损伤增加了神经元中的组蛋白甲基化,这被T3降低了 治疗。我们认为,这是受伤后T3保护的重要机制。我们也会 确定激活神经元再生和抗凋亡神经元后神经元的途径 低氧损伤。我们将利用TBI的体内啮齿动物模型来确定TH在保护和 促进脑损伤后恢复,并确定TBI后最佳的甲状腺马酮治疗。 我们将使用带有T3 reporter全局表达的鼠标来确定特定的大脑区域 受伤后T3作用降低,并评估受伤后对系统治疗的反应。 我们还将通过研究 调节水运输。我们将确定最佳的甲状腺激素制剂,剂量和 在TBI啮齿动物模型中促进脑恢复和中性再生的治疗时间表。这 对TH疗法的反应将包括通过成像,大脑特异性对脑病变的评估 基因表达和行为研究的模式。脑水肿和细胞死亡的减少,以及 神经元再生的促进应在脑损伤后产生有益的作用。这些研究 应该为临床策略提供指导,以减少脑损伤的影响和 促进康复。 呢

项目成果

期刊论文数量(0)
专著数量(0)
科研奖励数量(0)
会议论文数量(0)
专利数量(0)

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

数据更新时间:{{ journalArticles.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ monograph.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ sciAawards.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ conferencePapers.updateTime }}

{{ item.title }}
  • 作者:
    {{ item.author }}

数据更新时间:{{ patent.updateTime }}

GREGORY A BRENT其他文献

GREGORY A BRENT的其他文献

{{ item.title }}
{{ item.translation_title }}
  • DOI:
    {{ item.doi }}
  • 发表时间:
    {{ item.publish_year }}
  • 期刊:
  • 影响因子:
    {{ item.factor }}
  • 作者:
    {{ item.authors }}
  • 通讯作者:
    {{ item.author }}

{{ truncateString('GREGORY A BRENT', 18)}}的其他基金

Thyroid Hormone Receptor Isoform-Specific Actions
甲状腺激素受体亚型特异性作用
  • 批准号:
    8638458
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone and Retinoic Acid Regulation of Gene Expression
甲状腺激素和视黄酸对基因表达的调节
  • 批准号:
    8633738
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone Receptor Isoform-Specific Actions
甲状腺激素受体亚型特异性作用
  • 批准号:
    9222005
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone and Retinoic Acid Regulation of Gene Expression
甲状腺激素和视黄酸对基因表达的调节
  • 批准号:
    8811004
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone and Neuronal Protection
甲状腺激素和神经元保护
  • 批准号:
    10265398
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone and Retinoic Acid Regulation of Gene Expression
甲状腺激素和视黄酸对基因表达的调节
  • 批准号:
    8974308
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone and Neuronal Protection
甲状腺激素和神经元保护
  • 批准号:
    10455513
  • 财政年份:
    2014
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone Receptor Isoform-Specific Actions
甲状腺激素受体亚型特异性作用
  • 批准号:
    7017825
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone Receptor Isoform-Specific Actions
甲状腺激素受体亚型特异性作用
  • 批准号:
    6759725
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:
Thyroid Hormone Receptor Isoform-Specific Actions
甲状腺激素受体亚型特异性作用
  • 批准号:
    6850780
  • 财政年份:
    2004
  • 资助金额:
    --
  • 项目类别:

相似国自然基金

面向掌纹识别的安全与隐私保护理论和方法研究
  • 批准号:
    62376211
  • 批准年份:
    2023
  • 资助金额:
    49 万元
  • 项目类别:
    面上项目
微观市场均衡视角下中国长期护理保险试点的福利分析与政策评估
  • 批准号:
    72304093
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目
面向康复护理机器人的人机信任度评估方法与任务影响机制研究
  • 批准号:
    62306195
  • 批准年份:
    2023
  • 资助金额:
    30.00 万元
  • 项目类别:
    青年科学基金项目
基于生命质量的癌症患者心理行为与护理干预
  • 批准号:
    72381240026
  • 批准年份:
    2023
  • 资助金额:
    20 万元
  • 项目类别:
    国际(地区)合作与交流项目
天然水体中药品和个人护理品间接光降解产物预测模型的构建和应用
  • 批准号:
    42307496
  • 批准年份:
    2023
  • 资助金额:
    30 万元
  • 项目类别:
    青年科学基金项目

相似海外基金

Mitochondrial Dysfunction underlies treatment related hepatotoxicity in Hispanics with acute lymphoblastic leukemia
线粒体功能障碍是西班牙裔急性淋巴细胞白血病治疗相关肝毒性的基础
  • 批准号:
    10675403
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Targeting glioblastoma with CM93, a novel EGFR inhibitor with exceptional brain penetration
使用 CM93 靶向胶质母细胞瘤,这是一种具有出色脑渗透性的新型 EGFR 抑制剂
  • 批准号:
    10697498
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
Understanding the in vivo impact of immunotherapies in splenic lymphoma by intravital three-photon microscopy
通过活体三光子显微镜了解免疫疗法对脾淋巴瘤的体内影响
  • 批准号:
    10576013
  • 财政年份:
    2023
  • 资助金额:
    --
  • 项目类别:
MEK PATHWAY INHIBITION COMBINED WITH 5-AMINOLEVULINIC ACID-PHOTODYNAMIC THERAPY FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
MEK 通路抑制联合 5-氨基酮戊酸光动力疗法治疗弥漫性中线胶质瘤
  • 批准号:
    10733440
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
MEK PATHWAY INHIBITION COMBINED WITH 5-AMINOLEVULINIC ACID-PHOTODYNAMIC THERAPY FOR THE TREATMENT OF DIFFUSE MIDLINE GLIOMA
MEK 通路抑制联合 5-氨基酮戊酸光动力疗法治疗弥漫性中线胶质瘤
  • 批准号:
    10536455
  • 财政年份:
    2022
  • 资助金额:
    --
  • 项目类别:
{{ showInfoDetail.title }}

作者:{{ showInfoDetail.author }}

知道了